Aratana Therapeutics Inc Hits 5-Month High On Positive Developmen
After the announcement of positive results from the pivotal late-stage field study of its novel drug, AT-001 by Aratana Therapeutics Inc. (NASDAQ:PETX), its stock rose over 26% to $16.50. The drug is designed to treat osteoarthritis pain in dogs. The study demonstrated that at once-daily dosage, the dogs receiving the drug showed improvement in the…